Merck & Co Needs To Go Low On Price For New HIV Drugs In EU
Executive Summary
Pifeltro and Delstrigo have been backed for approval by the CHMP but how well they will fare on the market depends on a competitive pricing strategy and continuing to benefit from current European guidelines which recommend NNRTI-containing regimens for HIV.
You may also be interested in...
EU Approval Set For Three New Orphans And Lilly’s Emgality; Exondys Appeal Fails
The CHMP has upheld its previous negative opinion on Sarepta’s DMD treatment Exondys, but has given a raft of positive opinions on other novel products, including Lilly’s new migraine prophylactic Emgality, Spark Therapeutics’ gene therapy Luxturna for retinal dystrophy, and Vabomere, The Medicines Co/Rempex Pharmaceuticals’ new antibiotic for severe infections.
EU Approval Set For Three New Orphans And Lilly’s Emgality; Exondys Appeal Fails
The CHMP has upheld its previous negative opinion on Sarepta’s DMD treatment Exondys, but has given a raft of positive opinions on other novel products, including Lilly’s new migraine prophylactic Emgality, Spark Therapeutics’ gene therapy Luxturna for retinal dystrophy, and Vabomere, The Medicines Co/Rempex Pharmaceuticals’ new antibiotic for severe infections.
Pharma Giants Urge Biotechs To Get In Touch As Early As Possible
Although money is too tight to mention for some biotechs, last year the value of preclinical partnerships actually went up and Switzerland’s big two pharma players are on the lookout for more.